Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key focus areas.

The partnership will include a worldwide call for research proposals focused on new concepts for early disease interventions, particularly during adolescence, to normalize brain function, as well as new disease models...